

Revision date: 31-May-2013 Version: 1.0 Page 1 of 6

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Oprelvekin

Trade Name: Not applicable

Synonyms: Recombinant Interleukin-11, Neumega, Recombinant IL-11

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical active

Details of the Supplier of the Safety Data Sheet

Pfizer Global Manufacturing
Pfizer Ltd
Pfizer Inc
Ramsgate Road
235 East 42nd Street
New York, NY 10017
Sandwich, Kent
CT13 9NJ

United Kingdom +00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300 International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Appearance: Clear, colorless, solution

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

EU Classification:

Label Elements

Signal Word: Not Classified

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

Known Clinical Effects: Serious allergic reactions, including anaphylaxis, have been reported. Common adverse

effects include effects on cardiovascular system, fluid retention, swelling of the face, changes in blood pressure, irregular heartbeat (cardiac arrhythmia), visual disturbances, decreased red

blood cell count (anemia), stroke.

Australian Hazard Classification

(NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which

requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

MIDOOMO

Material Name: Oprelvekin Page 2 of 6
Revision date: 31-May-2013 Version: 1.0

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS	EU Classification	GHS Classification	%
		List		Classification	
Oprelvekin	145941-26-0	Not Listed	Not Listed	Not Listed	100

Additional Information: Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Exposure: Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Formation of toxic gases is possible during heating or fire.

Products:

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Material Name: Oprelvekin Page 3 of 6
Revision date: 31-May-2013 Version: 1.0

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

Collecting: area thoroughly.

Additional Consideration for Non-essential personnel should be evacuated from affected area. Report emergency

Large Spills: situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Restrict access to work area. Avoid open handling. Ground and bond all bulk transfer equipment. Minimize generating airborne mists and vapors. Use appropriate engineering controls to maintain exposures below the B-OEB taking all applicable routes of exposure into consideration. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. A change area to facilitate 'good laboratory/manufacturing' decontamination practices is recommended. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store at room temperature in properly labeled containers. Keep away from heat, sparks and

flames.

Specific end use(s): No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

The Biotherapeutic Occupational Exposure Band (B-OEB) is an acceptable daily intake (ADI) range, based on available hazard data with appropriate safety factors applied. Engineering control measures should be utilized to bring exposures into the relevant B-OEB; supplementary administrative controls and personal protective equipment are to be used to achieve exposure control to the bottom of the band.

Oprelvekin

Pfizer Occupational Exposure B-OEB 4 (control exposure to the range of 10 μg/day to <100 μg/day)

Band (OEB):

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. Use process

containment, local exhaust ventilation, biosafety cabinet, or other engineering controls to maintain airborne levels within the B-OEB range. It is recommended that all operations be fully

enclosed and no air recirculated.

Personal Protective Refer to applicable national standards and regulations in the selection and use of personal

Equipment: protective equipment (PPE).

Hands: Wear impervious, disposable gloves as minimum protection (double recommended).

Eves: Wear safety glasses as minimum protection.

Skin: Wear impervious protective clothing when handling this compound. Full body protection

recommended (scale dependent).

Respiratory protection: If airborne exposures are within or exceed the Biotherapeutic Occupational Exposure Band (B-

OEB) range, wear an appropriate respirator with a protection factor sufficient to control

exposures to the bottom of the B-OEB range.

Mixture

Material Name: Oprelvekin Page 4 of 6
Revision date: 31-May-2013 Version: 1.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:SolutionColor:Clear, colorlessOdor:No data available.Odor Threshold:No data available.

Molecular Formula: Mixture Molecular Weight:

Solvent Solubility: No data available Water Solubility: No data available

pH: 6.8-7.2

Melting/Freezing Point (°C):

Boiling Point (°C):

No data available.

No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

OprelvekinNo data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s):

Vapor Pressure (kPa):

Vapor Density (g/ml):

Relative Density:

No data available

Flammablity:

Autoignition Temperature (Solid) (°C):

Flammability (Solids):

Flash Point (Liquid) (°C):

Upper Explosive Limits (Liquid) (% by Vol.):

Lower Explosive Limits (Liquid) (% by Vol.):

No data available
No data available
No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition No data available

Products:

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

Acute Toxicity: (Species, Route, End Point, Dose)

Oprelvekin

Rat Intravenous Minimum Lethal Dose > 10 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Material Name: Oprelvekin Page 5 of 6
Revision date: 31-May-2013 Version: 1.0

11. TOXICOLOGICAL INFORMATION

Oprelvekin

4 Week(s) Monkey Subcutaneous10 μg/kg/day LOAEL Liver

28 Day(s) Rat Subcutaneous 1000 μg/kg/day NOAEL No effects at maximum dose

13 Week(s) Monkey Subcutaneous 1 µg/kg/day NOAEL Liver

13 Week(s) Dog Oral 30 mg/kg/day NOAEL No effects at maximum dose

26 Week(s) Rat Subcutaneous 2000 ug/kg/day NOAEL No effects at maximum dose

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Oprelvekin

Fertility and Embryonic Development Rat Subcutaneous10 ug/kg/day NOAEL Developmental toxicity, Fetotoxicity,

Maternal toxicity

Fertility and Embryonic Development Rabbit Subcutaneous 1 ug/kg/day NOAEL Fetotoxicity, Fetal mortality, Maternal

Toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Oprelvekin

In Vitro Bone Marrow Metaphase Analysis Human Lymphocytes Negative In Vitro Mammalian Cell Mutagenicity Mouse Lymphoma Negative

In Vivo Micronucleus Mouse Bone Marrow Negative

Carcinogen Status: Not listed as a carcinogen by IARC, NTP or US OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

Material Name: Oprelvekin Page 6 of 6
Revision date: 31-May-2013 Version: 1.0

10000m

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class:
None required

Oprelvekin

CERCLA/SARA 313 Emission reporting

California Proposition 65

EU EINECS/ELINCS List

Not Listed

Not Listed

16. OTHER INFORMATION

Data Sources: Pfizer proprietary drug development information.

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet